Mary Ann Gray
Chairman and Chief Executive Officer
United States of America
Dr. Gray has served as a member of the Senomyx Board of Directors since September 2010. Since 2003, Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray currently serves on the Boards of Directors of three other publicly traded biopharmaceutical companies, Dyax Corp., Acadia Pharmaceuticals, Inc., and TetraLogic Pharmaceuticals Corporation. At Dyax she is also the lead independent director. Dr. Gray holds a Ph.D. in pharmacology from the University of Vermont and a B.S. in biology from University of South Carolina.